JP2008530137A5 - - Google Patents

Info

Publication number

JP2008530137A5

JP2008530137A5 JP2007555369A JP2007555369A JP2008530137A5 JP 2008530137 A5 JP2008530137 A5 JP 2008530137A5 JP 2007555369 A JP2007555369 A JP 2007555369A JP 2007555369 A JP2007555369 A JP 2007555369A JP 2008530137 A5 JP2008530137 A5 JP 2008530137A5

Authority

JP

Japan

Prior art keywords

seq

pharmaceutical composition

skin

polypeptide

amino acid

Prior art date

2006-02-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 10
• 210000003491 skin Anatomy 0.000 claims 8
• 125000003275 alpha amino acid group Chemical group 0.000 claims 6
• 238000000034 method Methods 0.000 claims 6
• 229920001184 polypeptide Polymers 0.000 claims 6
• 102000004196 processed proteins & peptides Human genes 0.000 claims 6
• 108090000765 processed proteins & peptides Proteins 0.000 claims 6
• 210000001744 T-lymphocyte Anatomy 0.000 claims 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
• 239000005557 antagonist Substances 0.000 claims 4
• 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 3
• 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 3
• 241000124008 Mammalia Species 0.000 claims 3
• 206010012442 Dermatitis contact Diseases 0.000 claims 2
• 206010020751 Hypersensitivity Diseases 0.000 claims 2
• 206010034277 Pemphigoid Diseases 0.000 claims 2
• 208000003251 Pruritus Diseases 0.000 claims 2
• 241001303601 Rosacea Species 0.000 claims 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
• 206010047642 Vitiligo Diseases 0.000 claims 2
• 208000030961 allergic reaction Diseases 0.000 claims 2
• 208000004631 alopecia areata Diseases 0.000 claims 2
• 208000000594 bullous pemphigoid Diseases 0.000 claims 2
• 208000010247 contact dermatitis Diseases 0.000 claims 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
• 230000003111 delayed effect Effects 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 229940079593 drug Drugs 0.000 claims 2
• 210000004698 lymphocyte Anatomy 0.000 claims 2
• 201000005962 mycosis fungoides Diseases 0.000 claims 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
• 206010037844 rash Diseases 0.000 claims 2
• 201000004700 rosacea Diseases 0.000 claims 2
• 208000017520 skin disease Diseases 0.000 claims 2
• 208000010201 Exanthema Diseases 0.000 claims 1
• 208000009889 Herpes Simplex Diseases 0.000 claims 1
• 241000700584 Simplexvirus Species 0.000 claims 1
• 206010040844 Skin exfoliation Diseases 0.000 claims 1
• 208000032509 Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum Diseases 0.000 claims 1
• 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 1
• 241000700605 Viruses Species 0.000 claims 1
• 230000003213 activating effect Effects 0.000 claims 1
• 239000012472 biological sample Substances 0.000 claims 1
• 210000002615 epidermis Anatomy 0.000 claims 1
• 201000005884 exanthem Diseases 0.000 claims 1
• 230000004936 stimulating effect Effects 0.000 claims 1
• 238000010998 test method Methods 0.000 claims 1
• 230000004797 therapeutic response Effects 0.000 claims 1
• 231100000331 toxic Toxicity 0.000 claims 1
• 230000002588 toxic effect Effects 0.000 claims 1